Rhythm Pharmaceuticals (NASDAQ:RYTM) has outperformed the market over the past 5 years by 40.99% on

Deutsche Bank analyst David Hoang initiates coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) with

NVIDIA's blockbuster earnings sent shockwaves through tech on Thursday, but Wall Street analysts wer

Bank of New York Mellon Corp acquired a new position in Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)

Duquesne Family Office has beefed up its healthcare holdings.

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company foc

-- Approximately 5,000 to 8,000 patients estimated to be living with acquired HO in Japan --  -- Com

Rhythm Pharmaceuticals develops medicines for rare forms of obesity. The company has little competit

Rhythm Pharmaceuticals is transitioning from a single rare disease drug to a broad MC4R therapeutic

BOSTON, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global comm

Rhythm Pharmaceuticals NASDAQ: RYTM is expanding commercialization of its rare-disease obesity treat

Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) shares are trading higher on Wednesday.

Rhythm Pharma shares rise after U.K. expands Imcivree authorization for acquired hypothalamic obesit

JP Morgan analyst Priyanka Grover maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweigh

Rhythm Pharmaceuticals (NASDAQ: RYTM) reported second-quarter 2026 global net product sales of $71.3

Citigroup analyst Samantha Semenkow maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and

RBC Capital analyst Lisa Walter maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Outperform

Citizens analyst Jonathan Wolleben maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Market O

BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global comm

Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2026 Earnings Call Transcript

Rhythm Pharmaceuticals NASDAQ: RYTM reported second-quarter 2026 global net product sales of $71.3 m

Rhythm Pharmaceuticals (NASDAQ:RYTM) released second-quarter financial results and hosted an earning

Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.73 per share versus the Zac

Rhythm Pharmaceuticals said on Tuesday its experimental weekly injectable drug helped reduce body we

Rhythm Pharmaceuticals (NASDAQ:RYTM) reported quarterly losses of $(0.73) per share which beat the a

-- U.S. launch of IMCIVREE ® (setmelanotide) for acquired hypothalamic obesity (HO) starts strong wi

Eleven patients with acquired HO were enrolled in the ongoing, open-label trial. Key preliminary fin

-- -11.6% mean reduction in BMI from baseline at Week 16 (n=7) -- -- BMI reductions consistent with

Rhythm Pharmaceuticals (RYTM) possesses the right combination of the two key ingredients for a likel

JP Morgan analyst Priyanka Grover initiates coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) with

NEW YORK, July 21, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is inves

BOSTON, July 21, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global comm

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focu

RBC Capital analyst Lisa Walter maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Outperform

Canaccord Genuity analyst Whitney Ijem maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focu

Rhythm Pharma Phase 2 data showed improvements in BMI, body composition, hunger symptoms, and behavi

Wells Fargo analyst Derek Archila maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweigh

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI o

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focu

"Streamlining Diagnosis of Bardet-Biedl Syndrome: New Diagnostic Algorithm with Updated Criteria

Canaccord Genuity analyst Whitney Ijem maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy

Rhythm Pharmaceuticals (NASDAQ: RYTM) reported better-than-expected earnings, with strong demand for

RBC Capital analyst Lisa Walter maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Outperform

Wells Fargo analyst Derek Archila maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweigh

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focu

"This EC authorization is an important step toward making the first new treatment option availab

-- European Commission decision anticipated in second quarter of 2026 --BOSTON, March 26, 2026 (GLOB